These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34152944)

  • 1. Different long-term avidity maturation for IgG anti-spike and anti-nucleocapsid SARS-CoV-2 in hospitalized COVID-19 patients.
    Heireman L; Boelens J; Coorevits L; Verhasselt B; Vandendriessche S; Padalko E
    Acta Clin Belg; 2022 Jun; 77(3):653-657. PubMed ID: 34152944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
    Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
    J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete IgG avidity maturation after seasonal coronavirus infections.
    Struck F; Schreiner P; Staschik E; Wochinz-Richter K; Schulz S; Soutschek E; Motz M; Bauer G
    J Med Virol; 2022 Jan; 94(1):186-196. PubMed ID: 34427932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to SARS-CoV-2 nucleocapsid and spike proteins in hospitalized patients with COVID-19: A multicenter, retrospective, cross-sectional study in Japan.
    Hibino M; Watanabe S; Tobe S; Maeda K; Horiuchi S; Nishiguchi S; Iwase A; Uryu K; Kobayashi S; Kondo T
    Respir Investig; 2022 Mar; 60(2):256-263. PubMed ID: 34924308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation.
    Struck F; Schreiner P; Staschik E; Wochinz-Richter K; Schulz S; Soutschek E; Motz M; Bauer G
    J Med Virol; 2021 Dec; 93(12):6765-6777. PubMed ID: 34387884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection.
    Choudhary HR; Parai D; Dash GC; Peter A; Sahoo SK; Pattnaik M; Rout UK; Nanda RR; Pati S; Bhattacharya D
    Infection; 2021 Oct; 49(5):1045-1048. PubMed ID: 34213733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of IgG-avidity and antibody levels after Covid-19.
    Löfström E; Eringfält A; Kötz A; Wickbom F; Tham J; Lingman M; Nygren JM; Undén J
    J Clin Virol; 2021 Nov; 144():104986. PubMed ID: 34563862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity.
    Hajilooi M; Keramat F; Moazenian A; Rastegari-Pouyani M; Solgi G
    Med Microbiol Immunol; 2023 Jun; 212(3):203-220. PubMed ID: 37103583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of avidity determination in SARS-CoV-2 serology.
    Bauer G; Struck F; Schreiner P; Staschik E; Soutschek E; Motz M
    J Med Virol; 2021 May; 93(5):3092-3104. PubMed ID: 33565617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination.
    Garcia L; Woudenberg T; Rosado J; Dyer AH; Donnadieu F; Planas D; Bruel T; Schwartz O; Prazuck T; Velay A; Fafi-Kremer S; Batten I; Reddy C; Connolly E; McElheron M; Kennelly SP; Bourke NM; White MT; Pelleau S
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens.
    Rezaei M; Sadeghi M; Korourian A; Tabarsi P; Porabdollah M; Askari E; Mortaz E; Mahmoudi S; Marjani M; Velayati AA
    Hum Antibodies; 2021; 29(2):109-113. PubMed ID: 33720878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2.
    Bauer G
    Int J Infect Dis; 2021 May; 106():61-64. PubMed ID: 33713819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
    Huergo LF; Paula NM; Gonçalves ACA; Kluge CHS; Marins PHSA; Camargo HSC; Sant'Ana TP; Farias LRP; Aldrighi JD; Lima ÊS; Jacotenski GT; Vargas LR; Costa G; Weissheimer KV; Nazário MG; Teixeira KN; Conzentino MS
    Microbiol Spectr; 2022 Aug; 10(4):e0102622. PubMed ID: 35770982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
    Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
    Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination.
    Du J; Zhang D; Pathakamuri JA; Kuebler D; Yang Y; Loginova Y; Chu E; Madej R; Neves JV; Singer B; Radke H; Spencer N; Rizk E; Zhang A; Lu CM; Sha MY
    Emerg Microbes Infect; 2022 Dec; 11(1):250-259. PubMed ID: 34951566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.
    Portilho AI; Silva VO; Ahagon CM; Matsuda EM; de Oliveira EL; da Silveira EPR; de Souza Lima AK; Lindoso JAL; de Campos IB; Hong MA; De Gaspari E; de Macedo Brígido LF
    J Med Virol; 2022 Jan; 94(1):178-185. PubMed ID: 34428312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
    Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
    J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.